Health Matters
Printing is not available for Health Matters content.
Subscribers can read every article in full at health-matters.io.

Healthcare news and intelligence for Southern Africa

Daily reporting for the pharmaceutical, medical scheme and hospital sectors, published by Health Matters since 1994.

12.11.2026

Aspen wins generic semaglutide approval in South Africa and Brazil, with launches planned in coming months. Read what this means for diabetes care.

Latest

More news

05.11.2026

Rare disease funding is under scrutiny after the KeyHealth ruling. See how schemes could share the cost of treatments such as Ultomiris.

05.11.2026

Essential medicine shortages threaten 165 public sector products in South Africa. See what is disrupting supply and how the department is responding.

05.11.2026

Retail pharmacy competition is squeezing Dis-Chem’s earnings as Clicks expands loyalty discounts. Shoprite’s Sixty60 is also in focus.

05.11.2026

Value-based care could help South Africa curb private healthcare costs while NHI remains contested. Read why payment reform need not wait.

03.11.2026

A KeyHealth PMB ruling orders full funding for treatment for a teenager’s rare blood disorder. The scheme plans to challenge the decision.

03.11.2026

Aspen Ovestin sale will raise €197m while preserving a manufacturing role. Explore the deal terms and implications for its portfolio strategy.

02.11.2026

A healthcare consensus initiative seeks agreement on universal coverage and action on failing services. Read about its priorities.

02.11.2026

Explore the Dis-Chem digital platform and see how it connects prescriptions and shopping in a seamless online experience.

30.10.2026

Western Cape urges national action on medicine shortages and possible port delays affecting public healthcare.

30.10.2026

China clinical trials offer drugmakers lower costs and faster recruitment, but safety and data concerns persist.

28.10.2026

Medical scheme increases in 2027 range from 7.35% to 8.9%. Ageing members, chronic illness and medicine costs drive contributions higher.

28.10.2026

GLP-1 obesity treatment remains unavailable in the public sector as officials delay a review despite WHO guidance. Read about the barriers.

Free every Friday

Health Matters Weekly

Not ready to subscribe? Get the week’s most important Southern African healthcare stories, with what they mean for the industry, in one free email.

The archive

Browse every Health Matters article by month.

Get Health Matters every day

Subscribe for the daily briefing, every article in full and the complete archive. Corporate plans cover up to 10 people.

SubscribeLog in